Summary

The Most Favored Nation (MFN) policy has turned prices in other countries into a benchmark for the US pharmaceutical market. Daniel Suhr, Two Scenarios, looks at MFN from a European perspective and discusses what it means for launch sequencing, list prices, discounts and international reference pricing when the price offered in a European market can influence the price in the US. The session also covers the latest developments and asks whether the importance of MFN has been overstated, separating what is already visible in company behavior from political noise.

Speaker
Daniel Suhr has been CEO of Two Scenarios for 15 years. The consultancy specialises in global pharmaceutical pricing with a strong focus on international reference pricing. Daniel has worked on global pricing projects for numerous companies based both in Europe and the US. Prior to Two Scenarios, Daniel spent 12 years in major pharmaceutical companies. He holds a Master of Science in International Business

Atrium Pulse
Is our webinar series made to inspire and connect life science professionals with the experts shaping the industry’s future.
Every two weeks, we pair 15 minutes of sharp insight from a leading voice in the field with 15 minutes of live Q&A - free, online, and open to everyone curious about where life science is heading.

Key words

• Market Access
• Pharmaceutical Pricing
• International Reference Pricing
• Most Favoured Nation (MFN)
• Global Pricing Strategy